sVCAM－1、sPECAM－1在慢性阻塞性肺疾病中的检测及临床意义

目的探讨可溶性血管细胞间粘附分子－1（sVCAM－1）和可溶性血小板内皮细胞黏附分子－1（sPECAM-1）在慢性阻塞性肺疾病（COPD）发病中的作用。方法病例来自我院呼吸科住院和门诊病人，采用酶联免疫吸附测定法（ELISA）检测20例健康成人（对照组）、35例COPD急性加重期患者（COPD组）治疗前后血浆中sVCAM－1和sPECAM—1的水平。结果sVCAM－1在COPD治疗前组（10．94±5．26）nmol／L]明显高于治疗后组（8．32±4．24）nmol／L]及对照组（7．34±3．68）nmol／L]，差异有统计学意义（q=2．24、2．75，P均〈0．05），而治疗后组与对照组差异无统计学意义（q=0．75，P=0．455）；sPECAM-1在COPD治疗后组（61．01±12．53）pmol／L]明显高于治疗前组（35．99±8．05）pmol／L]及对照组（43．11±10．41）pmol／L]，差异有统计学意义（q19．23、5．91，P均（0．1301），且对照组亦显著高于治疗前组（q=2．35，P=0．021）。结论sVCAM-1在COPD急性加重期患者显著增高，提示sVCAM-1可作为判断COPD病情严重程度和疗效的指标；sPECAM-1在COPD治疗后显著增高，可能在COPD病程中起保护性作用。

Detection and clinical significance of sVCAM-1 and sPECAM-1 in chronic obstructive pulmonary disease

Objective To explore the role of sVCAM-1 and sPECAM-1 of prethrombotic state mediator in patients with chronic obstructive pulmonary disease （COPD）. Methods To detect the levels of sVCAM-1 and sPECAM-1 in blood plasma of 20 cases with healthy（control group） and 35 cases with COPD group before treatment and post-treatment plasma with ELISA,respectively.Results The level of sVCAM-1 in before treatment group （ 10.94±5.26）nmol/L] was significantly higher than those of post-treatment group （8.32±4.24）nmol/L] and control group （7.34±3.68）nmol/L] （q=2.24,2.75, both P〈0.001）and the difference of sVCAM-lbetween the post-treatment group and the control group was not significant （q= 0.75,P=0.455）.The level of sPECAM-1 in post-treatment group （61.01±12.53）pmol/L] was significantly higher than those of before treatment group （35.99±8.05）pmol/L] and control group （43.11±10.41 ）pmol/L]（q=9.23,5.91, beth P〈0.001 ）,the level of control group was also obviously higher than the before treatment group （q=2.35 ,P=0.021 ）.Conclusions The levels of sVCAM-1 increase significantly during acute exacerbation stage of COP]） ,which may evaluate the curative effect of COPD. The significant increasing of sPECAM-1 in plasma of post-treatment group suggests that sPECAM-1 may be a protective factor during COPD.